Researchers have developed a blood test that can more accurately assess if Alzheimer's disease is impacting a person's cognitive abilities by detecting a specific biomarker, MTBR-tau243. This test complements a spinal fluid test and provides stronger predictive value regarding memory loss and dementia stages. Unlike tests that solely measure amyloid plaques, which can exist without symptoms, the new tests focus on tau tangles, a hallmark of Alzheimer's that correlates more closely with cognitive decline. These advancements aim to better inform treatment options for patients and were made possible by NIH funding.
Dr. Randall Bateman emphasizes that while amyloid plaques indicate potential Alzheimer's presence, they do not necessarily reflect cognitive impairment, highlighting the need for better diagnostic tests.
Tony Wyss-Coray notes that the new blood and spinal fluid tests could significantly aid in diagnosing Alzheimer's by indicating whether it affects memory and cognitive function.
Collection
[
|
...
]